A1/A2 polymorphism of the glycoprotein IIIa gene and diabetic retinopathy in Caucasians with type 2 diabetes
Version of Record online: 4 APR 2011
© 2011 The Authors. Clinical and Experimental Ophthalmology © 2011 Royal Australian and New Zealand College of Ophthalmologists
Clinical & Experimental Ophthalmology
Volume 39, Issue 7, pages 665–672, September/October 2011
How to Cite
Nikolajević-Starčević, J., Petrovič, M. G. and Petrovič, D. (2011), A1/A2 polymorphism of the glycoprotein IIIa gene and diabetic retinopathy in Caucasians with type 2 diabetes. Clinical & Experimental Ophthalmology, 39: 665–672. doi: 10.1111/j.1442-9071.2011.02520.x
- Issue online: 3 OCT 2011
- Version of Record online: 4 APR 2011
- Accepted manuscript online: 7 FEB 2011 10:41AM EST
- Received 13 August 2010; accepted 4 January 2011.
- diabetic retinopathy;
- genetic risk factor;
- glycoprotein IIIa PlA1/A2 polymorphism
Background: A PlA1/A2 polymorphism of glycoprotein IIIa is known to be involved in the pathogenesis of arterial thrombosis, myocardial infarction, stroke and type 2 diabetes, but there is no evidence of association with diabetic retinopathy. The aim of this study was to examine the role of the PlA1/A2 polymorphism of the glycoprotein IIIa gene in the development of diabetic retinopathy in Caucasians with type 2 diabetes.
Design: Cross-sectional case–control study.
Participants: Totally 222 patients with diabetic retinopathy and 120 diabetic subjects without clinical signs of diabetic retinopathy from the Eye Clinic, University Medical Centre Ljubljana were enrolled in the study.
Methods: Fundus examination and blood biochemical analysis were performed. The polymerase chain reaction and restriction fragment length polymorphism were used.
Main Outcome Measures: The total cholesterol, triglyceride, high-density lipoprotein levels, fasting blood glucose and HbA1c were measured, and the genotypes of the PlA1/A2 polymorphism were determined.
Results: Patients with diabetic retinopathy had earlier onset, longer duration of type 2 diabetes and a higher incidence of insulin therapy compared to the diabetic patients without diabetic retinopathy. A significantly lower frequency of the A2A2 genotype of glycoprotein IIIa was found in diabetic patients with retinopathy compared to those without retinopathy (odds ratio = 0.49, 95% confidence interval = 0.28–0.89; P = 0.018).
Conclusions: The A2A2 genotype of the glycoprotein IIIa polymorphism was associated with lower risk for diabetic retinopathy in Caucasians with type 2 diabetes. Further studies are needed to elucidate its protective role in the development of diabetic retinopathy in Caucasians.